Monthly Prescribing Reference

Cabenuva Label Update Makes Oral Lead-In Dosing Optional

Cabenuva injection is a 2-drug co-packaged product that combines cabotegravir, an HIV integrase strand transfer inhibitor, and rilpivirine, an HIV non-nucleoside reverse transcriptase inhibitor. The ...
Clinical Trials Arena on MSN

ViiV’s two-monthly HIV jab bests daily oral drugs in African teenagers

The LATA study pitted Cabenuva against a triple therapy in teenagers aged 12 to 19 with HIV in Africa.
Nasdaq

ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV ...

Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine ...

Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

Among healthcare providers, 89% (n=16/18) reported a positive overall opinion of administering CAB LA for PrEP in their practice. Prescribers cited benefits of regular injection visits, including ...
Medscape

FDA Approves HIV Injectable Cabenuva Initiation Without Oral Lead-in

Initiating treatment may become easier for adults living with HIV. The US Food and Drug Administration has approved a label update that allows adults living with HIV to begin treatment with Cabenuva ...
Fox 5 San Diego

U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen

CABENUVA offers virologically suppressed adolescents 12 years of age or older living with HIV-1 an injectable treatment option with as few as six dosing days per year TITUSVILLE, N.J., March 29, 2022 ...
Medscape

Long-Acting HIV ART: Lessons From a Year of Cabenuva

One year into offering the first long-acting injectable HIV treatment to his patients, Jonathan Angel, MD, head of the Division of Infectious Diseases at the University of Ottawa, Ontario, Canada, ...
Business Wire

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer and Shionogi as shareholders, today announced an exclusive ...